	T A	A = -1! 4/ - )
Notice of Allowability	Application No.	Applicant(s)
	10/781,850	TOFOVIC ET AL.
	Examiner	Art Unit
	San-ming Hui	1617
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313  1. This communication is responsive to October 5, 2006.  2. The allowed claim(s) is/are 1,2,4-6,8-10,12-14,16-18,20-23  3. Acknowledgment is made of a claim for foreign priority unestable and the priority documents have a compared to the priority	(OR REMAINS) CLOSED in this a or other appropriate communicati IGHTS. This application is subject 3 and MPEP 1308.  2,24-26,28-30,32-34 and 36.  Inder 35 U.S.C. § 119(a)-(d) or (f).  The been received.  The been received in Application No. Icuments have been received in the of this communication to file a rep	correspondence address application. If not included on will be mailed in due course. THIS t to withdrawal from issue at the initiative
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)  1. Notice of References Cited (PTO-892)	5. Notice of Informa	I Patent Application
Notice of Preferences Sites (170-632)     Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summa Paper No./Mail D	ıry (PTO-413),
3. Information Disclosure Statements (PTO/SB/08),	7. Examiner's Amer	
Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's State	ment of Reasons for Allowance
of Biological Material	9.	
		·
		•

Application/Control Number: 10/781,850

Art Unit: 1617

## **DETAILED ACTION**

Applicant's response filed October 5, 2006 have been entered.

## **REASONS FOR ALLOWANCE**

The following is an examiner's statement of reasons for allowance: Applicant's remarks on the teachings of the cited prior arts, especially, '751 have been considered, and are found persuasive. Therefore, the rejection under 35 USC 103(a) is withdrawn. The cited prior arts fail to teach or fairly suggest the instant method of employing the estradiol metabolite for the treatment of pulmonary hypertension and heart failure.

US 2003/0050294 ('294) is the closest prior arts for the treatment of heart failure. '294 discloses a method of treating metabolic syndromes and its associated renal dysfunction employing the instant compounds.

It is noted that co-pending application 11/431,180 containing claims that are conflicting with the instant claims. However, since the provisional obviousness double patenting rejection would be the only rejection in the instant case, such rejection is not made. And the instant application will be passed to issue. Once the patent is granted, an obvious double patenting will be made against 11/431,180.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Claims 1-2, 4-6, 8-10, 12-14, 16-18, 20-22, 24-26, 28-30, 32-34 and 36 are allowed.

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

San-ming Hu/ Primary Examiner

Art Unit 1617